Acesso livre
Acesso livre

Infectologia

Perspectiva | Fabricantes de vacinas contra COVID-19 se planejam para os reforços anuais, mas não está claro se isso será necessário.

25 Nov, 2021 | 15:15h

COVID-19 Vaccine Makers Plan for Annual Boosters, but It’s Not Clear They’ll Be Needed – JAMA

As vacinas protegem contra a “long COVID”? O que dizem os dados – “Vacinas reduzem o risco de desenvolvimento de COVID-19 – mas os estudos discordam quanto à proteção contra ‘long COVID’”.

25 Nov, 2021 | 15:14h

Do vaccines protect against long COVID? What the data say – Nature

Conteúdos relacionados:

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

Comentário no Twitter

 

Aposta de Cuba nas vacinas contra COVID produzidas no país está valendo a pena.

25 Nov, 2021 | 15:11h

Cuba’s bet on home-grown COVID vaccines is paying off – Nature

OMS lança o relatório 2021 de resistência do HIV a medicamentos.

25 Nov, 2021 | 15:10h

Comunicado de imprensa: WHO releases HIV drug resistance report 2021 – World Health Organization

Relatório: HIV drug resistance report 2021 – World Health Organization

Ficha técnica: HIV Drug Resistance – World Health Organization

 

Comentário no Twitter

 

OMS emite diretrizes sobre o tratamento de crianças com síndrome inflamatória multissistêmica associada a COVID-19.

24 Nov, 2021 | 11:37h

Comunicado de imprensa: WHO issues guidelines on the treatment of children with multisystem inflammatory syndrome associated with COVID-19 – World Health Organization

Diretriz: Living guidance for clinical management of COVID-19 – World Health Organziation

Conteúdos relacionados:

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2.

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Opinião de 32 ministros de saúde: o mundo precisa agir agora e se preparar para futuras emergências de saúde.

24 Nov, 2021 | 11:36h

The world must act now to be prepared for future health emergencies – The BMJ

Conteúdos relacionados:

Viewpoint | Strengthening global health security and reforming the international health regulations: making the world safer from future pandemics.

Perspective | Learning from crisis: building resilient systems to combat future pandemics.

Systematic review: Border controls, restricted entry, quarantine essential for curbing COVID-19 and future pandemics.

Opinion | The future of pandemic preparedness: agile coordination around clinical trials.

UN Report: Preventing the Next Pandemic – Zoonotic Diseases and How to Break the Chain of Transmission

 

Comentário no Twitter

 

Revisão | Infecção fúngica invasiva associada à COVID-19.

24 Nov, 2021 | 11:34h

COVID-19-associated Invasive Fungal Infection – Open Forum Infectious Diseases

Conteúdos relacionados:

Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.

M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.

Consensus Guideline: Defining and managing COVID-19-associated pulmonary aspergillosis

Bacterial and fungal superinfections in critically ill patients with COVID-19

Invasive Fungal Disease complicating COVID-19: when it rains it pours

A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU

Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients

 

Comentário no Twitter

 

Promoção da aceitação das vacinas contra COVID-19: recomendações da comissão do Lancet sobre recusa de vacina, aceitação e demanda nos EUA.

24 Nov, 2021 | 11:32h

Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA – The Lancet

Conteúdo relacionado: WHO Guidance for improving acceptance and uptake of COVID-19 vaccines

Esperava-se que pessoas com asma sofressem mais durante a pandemia de COVID. No entanto, isso não ocorreu.

24 Nov, 2021 | 11:31h

We expected people with asthma to fare worse during COVID. Turns out they’ve had a break – The Conversation

Revisão sistemática | Vacinas para prevenção da diarreia causada por rotavírus.

24 Nov, 2021 | 11:06h

Vaccines for preventing rotavirus diarrhoea: vaccines in use – Cochrane Library

Resumo: Are rotavirus vaccines safe and effective in preventing rotavirus diarrhoea in infants and children? – Cochrane Library

Comentário: Vaccines for preventing rotavirus diarrhoea: an updated Cochrane review – Cochrane Library

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.